SOM Biotech announces the closure of an internal round for €5.5 Million

Barcelona, Spain. March 12, 2024. SOM Biotech ("SOM" or the "Company"), a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, announces the closure of an internal round for € 5.5 million to secure the completion of the Phase IIb study on Huntington patients with its lead candidate SOM3355.

SOM3355 is a small molecule with an important history of safety in the treatment of hypertension and angina pectoris in Europe and Asia, currently marketed in a few Asian countries only, while never approved in the US. It is a peculiar VMAT2 inhibitor (Vesicular Monoamine Transporter subtype 2 inhibitor) with a different chemical structure from all other VMAT2 inhibitors, justifying its extremely safe profile. SOM run a Phase IIa study in Huntington disease patients with chorea confirming its tolerability also in these patients' population, with no sign of depression, suicide or even sedation while showing clinical efficacy, that makes SOM3355 a candidate for a safer and effective treatment to suppress the involuntary jerking and writhing movements associated with the disease. The Company is running a Phase IIb clinical study with a protocol endorsed by the EHDN (European Huntington's Disease Network) and the CHDI (Huntington Study Group's clinical research organization). Preliminary data are expected in 3Q2024 and final report in 4Q2024; based on the study outcome the company may decide to ask for a conditional approval.

About SOM Biotech: SOM Biotech (www.sombiotech.com) is a Spanish Headquartered biopharmaceutical company founded in 2009. It is based on a unique proprietary artificial intelligence (AI) platform (*SOM^{AI}PRO*) to identify new mechanism of actions of small molecules dugs for the treatment of diseases with high unmet medical need with a focus on orphan disorders in the CNS space. *SOM^{AI}PRO* is the only AI drug discovery platform whose products achieved positive Phase II data in patients, demonstrating the high clinical predictive value of the platform. SOM leverages on an extensive pipeline of products developed for the treatment of orphan indications including TTR Amyloidosis, Huntington's disease, Phenylketonuria, Duchenne Muscular Dystrophy and Tardive Dyskinesia. TTR Amyloidosis product was licensed out upon positive Phase IIa data.

SOM is led by an experienced team with a successful track record in both drug development and AI platforms development.

For more information about SOM Biotech, please contact:

info@sombiotech.com